Gotaric

Gotaric is a prescription oral medication that contains the active ingredient febuxostat, a selective non‑purine xanthine oxidase inhibitor. It is marketed in the European Union and is supplied in tablet form, though specific strength information is not disclosed. By inhibiting xanthine oxidase, Gotaric reduces the production of uric acid, which is a key factor in the management of gout and hyperuricemia for patients who require long‑term uric‑acid control.

Gotaric is indicated for the treatment of conditions associated with elevated serum uric acid levels, primarily gout and chronic hyperuricemia.

- Management of acute gout attacks when used in conjunction with standard anti‑inflammatory therapy. - Long‑term prevention of gout flares in patients with a history of recurrent attacks. - Reduction of serum uric acid in patients diagnosed with chronic hyperuricemia. - Adjunct therapy for patients who have an inadequate response or intolerance to allopurinol. - Maintenance of target uric‑acid levels as part of a comprehensive gout management plan.

The safety profile of Gotaric includes a range of observed adverse events, which are generally categorized by frequency and severity.

Common: - Mild to moderate headache, often transient. - Nausea, vomiting, or abdominal discomfort that may improve with food. - Diarrhea or loose stools, occasionally accompanied by flatulence. - Elevated liver enzymes (ALT, AST) detected in routine laboratory monitoring.

Serious: - Severe hypersensitivity reactions, including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic failure or significant liver injury manifested by jaundice, elevated bilirubin, or coagulopathy. - Cardiovascular events such as myocardial infarction, unstable angina, or stroke, particularly in patients with pre‑existing risk factors.

Before initiating Gotaric, clinicians should evaluate patient history and laboratory values to identify factors that may increase the risk of adverse outcomes.

- Assess baseline liver function tests; avoid use in patients with active hepatic disease. - Review cardiovascular history, as the drug may be associated with ischemic events. - Monitor serum uric acid and renal function periodically during therapy. - Use caution in patients with a known hypersensitivity to febuxostat or other xanthine oxidase inhibitors. - Evaluate for concomitant use of azathioprine or mercaptopurine, which may require dose adjustment. - Consider pregnancy and lactation status; safety data are limited.

Gotaric may interact with other medicines, altering its effectiveness or increasing the risk of toxicity; relevant interactions are grouped below.

Avoid: - Concomitant use with azathioprine or mercaptopurine, which can lead to increased toxicity of these immunosuppressants. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) that may reduce febuxostat plasma concentrations.

Use with caution: - Warfarin, as febuxostat may enhance anticoagulant effect and require INR monitoring. - Antihypertensive agents, particularly diuretics, because changes in uric acid may affect blood pressure control. - NSAIDs or colchicine used for gout flares, to monitor for additive gastrointestinal side effects.